EGFR and non-small cell lung carcinoma: Similarly, single agent mifepristone has provided marked palliative benefits and extension of life for two women with NSCLC, with brain metastasis, who were positive for the epidermal growth factor receptor (EGFR) mutation, who progressed despite treatment with the third-generation tyrosine kinase inhibitor osimertinib [101].